ArticleJournal of the American Heart Association2025
Comparing 3 Evidence-Based Strategies to Reduce Cardiovascular Disease Burden: An Individual-Based Cardiometabolic Policy Simulation.
Article in Journal of the American Heart Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
backgroundUnderstanding the real-world impact of clinical trials that change risk factors is important for health policy. We developed a microsimulation that estimates the population-level benefits in each US state of cardiometabolic interventions.
methodsWe designed a state-specific agent-based simulation model with 51 million in silico individuals and estimated results for 2023 to 2040. Input data reflected current cardiometabolic health and the effects of interventions and risk factors. We constructed 3 health policy intervention scenarios based on randomized controlled trials proven to improve cardiometabolic population health: improved access to fixed-dose combination antihypertensive medication, a pharmacist-led intervention with phone-based reminders to increase adherence to statin and antihypertensive medications at the time they are initiated, and a community-based lifestyle and behavior intervention designed to prevent diabetes. Outcomes included CVD events, deaths, and disability-adjusted life years (DALYs).
resultsOur simulation included a representative population of the United States, accurate at the age, sex, and state level. By 2040, the fixed-dose combination intervention was estimated to have prevented 776 000 (95% uncertainty interval, 578 000-956 000) CVD DALYs and 44 600 (95% uncertainty interval, 32 700-55 600) deaths annually. The pharmacist-led intervention prevented 170 000 (95% uncertainty interval, 129 000-208 000) CVD DALYs, and the community-based intervention prevented 152 000 (95% uncertainty interval, 128 000-173 000) CVD DALYs.
conclusionsA fixed-dose combination of antihypertensives could prevent 1.2% of total CVD DALYs, with smaller benefits from adherence and lifestyle-focused programs. Impact of interventions varied by state. Providing accurate population-level estimates can help local health policy decision-makers implement the most impactful interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.